GLP-1 Race Heats Up with Positive Test Results for Next-Gen Eli Lilly Drug

GLP-1 Race Heats Up with Positive Test Results for Next-Gen Eli Lilly Drug

Lilly didn’t just move the needle, it broke the scale.  Results of a late-stage trial show that Type 2 diabetes patients using Eli Lilly’s highly anticipated next-generation weight-loss drug retatrutide experienced a significant reduction in blood-sugar levels and weight loss, the drug manufacturer said last week. The drug, an injectable taken once a week, helped patients on the highest dose lose 15.3% of their body weight on average and lower t…